Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources

ESMO Targeted Anticancer Therapies Congress 2025

03 - 05 Mar 2025

Paris, France

ESMO-TAT-2025-1000x1000

Abstracts and ePosters: Open Access
Slides and Webcasts: Available to ESMO Members and registered delegates, subject to presenters' consent

The copyright protected educational resources from this event are for personal usage only and not to be shared with any third parties. ESMO thanks the authors for their generosity.

Meeting programme Next/upcoming meetings

The ESMO TAT Congress is dedicated to improving the conduct of early phase clinical trials in oncology by providing the latest scientific breakthroughs as well as workshops and educational reviews on pre-clinical and early clinical data.ESMO TAT 2025 is a multi-stakeholder forum in the early drug development arena, which bring together investigators from academia, translational scientists, methodological experts and opinion leaders from industry, investor and regulatory bodies to highlight new data, promote collaboration and tackle challenges for accelerating the bench-to-bedside pathway to the benefit of our patients

Click here to access the official Abstract book of the ESMO Targeted Anticancer Therapies, a supplement to ESMO Open.

Resources from ESMO Colloquia
Hide
Filter by:
Search:
Reset

There are 203 resources available

Q&A and discussion

Session: Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development

Resources:

Webcast

The clinical/academia perspective

Presenter: Stefan Michiels

Session: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views

Resources:

Slides

Webcast

The regulator perspective

Presenter: Harpreet Singh

Session: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views

Resources:

Slides

Webcast

The biotech perspective

Presenter: Robert Doebele

Session: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views

Resources:

Slides

Webcast

The pharma perspective

Presenter: Walter Bordogna

Session: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.